Development of a novel antibacterial agent against Pseudomonas aeruginosa

点击翻译按钮获取中文摘要

Phico is developing a novel antibacterial technology called SASPject, that can be targeted to selected harmful bacteria. SASPject is not affected by antibiotic resistance mechanisms and works by disabling bacterial DNA in a way that bacteria cannot avoid. This project will enable Phico to complete the pre-clinical development of SASPject PT3 targeted to Pseudomonas aeruginosa (Pa). Intrinsically resistant to many antibiotics, Pa caused ~40M days of hospital therapy in 2010 due to a wide range of infections. In this 18 month project Phico will extend efficacy data to determine the best dosing strategy in humans. Phico will also develop a manufacturing process to 15L and then transfer the process to a contract manufacturer who will scale up to a 50L GMP-ready process and produce material for a safety study. A lyophilisation process will also be developed. The safety study conducted during this project will provide sufficient data to support a clinical trial application, making SASPject PT3 ready to test in a Phase I trial.